Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07032103

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.

  • Registration after informed consent.
  • Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
  • Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
  • Regular monitoring disease status and update of survival status
  • Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
  • 20 years
  • Patients requiring systemic chemotherapy with curative intent
  • Written informed consent

Exclusion criteria

  • Myeloid malignancy
  • Multiple myeloma
  • Patients do not require systemic chemotherapy with curative intent

Treatment and study plan

Immunochemotherapy

Drug

Systemic chemotherapy with curative intent

Other names: Supportive treatment

Primary outcomes

  1. Reponse rate

    Time frame: 3 months after the completion of treatment

    Repsonse to the ist line treatment

  2. Response

    Time frame: 3 months after chemotherapy

    response to treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Seok Jin Kim, MD., PhD.

CONTACT

[email protected]

+82234101766

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

A Prospective Study for Patients With Lymphoma at the Samsung Medical Center

Acronym: SMCLYM-IV

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Jun 22, 2025
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.